Ainos soars on positive pre-clinical results for Omicron Covid treatment

Ainos

30/09/2022 16:55

** Shares of biotech and medical research company Ainos Inc
 AIMD.O  jump ~45% to $2
    ** Stock will log its best day in over two months, if gains
hold
    ** AIMD announced positive results from its antiviral
efficacy study of VELDONA, a low-dose oral treatment, in
hamsters against the Omicron variant of SARS-CoV-2  urn:newsml:reuters.com:*:nACSv202xa
    ** Says it submitted an application for U.S. FDA Phase 2
clinical trials to evaluate the efficacy of VELDONA in patients
with mild COVID
    ** More than 58 mln shares trade, 1,400 times their 25-day
moving avg
    ** Accounting for session gains, stock down 84% YTD
 (Reporting by Arshreet Singh in Bengaluru)
 ((arshreet.singh@thomsonreuters.com
Twitter: https://twitter.com/Arshreets))